Condition: Esophageal Squamous Cell Carcinoma · Sponsor: Zhejiang Cancer Hospital
To observe the 1-year disease-free survival rate （1-year PFS） of patients with resectable esophageal squamous cell carcinoma who received neoadjuvant chemoradiotherapy combined with camrelizumab and achieved clinical complete remission with watchful waiting strategy.
This description comes directly from the study's public registry record.
Qixun Chen · +86-13958108371 · chenqixun64@163.com
Yongling Ji · +86-13958085251
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) | Hanzhou, Zhejiang, China | Not Yet Recruiting |
| Zhejiang Cancer Hospital | Hanzhou, Zhejiang, China | Recruiting |
| Ningbo Medical Center Lihuili Hospital | Ningbo, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05507411